The development of cardiac hypertrophy is a complicated process, which undergoes a transition from compensatory hypertrophy to heart failure, and the identification of new biomarkers and targets for this disease is greatly needed. Here we investigated the development of isoproterenol (ISO)-induced cardiac hypertrophy in an in vitro experimental model. After the induction of hypertrophy with ISO treatment in H9c2 cells, cell surface area, cell viability, cellular reactive oxygen species (ROS), and nitric oxide (NO) levels were tested. Our data showed that the cell viability, mitochondrial membrane potential, and NO/ROS balance varied during the development of cardiac hypertrophy in H9c2 cells. It was also found that the expression of thioredoxin1 (Trx1) and peroxiredoxin2 (Prdx2) was decreased during the cardiac hypertrophy of H9c2 cells. These results suggest a critical role for Trx1 and Prdx2 in the cardiac hypertrophy of H9c2 cells and in the transition from compensated hypertrophy to de-compensated hypertrophy in H9c2 cells, and our findings may have important implications for the management of this disease.
Introduction
Cardiac hypertrophy, an adaptive process in various physiological and pathological conditions, is an independent risk factor for heart failure and increased morbidity and mortality [1] [2] [3] . Cardiac hypertrophy is characterized by increased myocyte surface area and upregulation of fetal genes, such as atrial natriuretic peptide (ANP), β-myosin heavy chain (β-MHC), and natriuretic peptic (BNP) [4] . It has been reported that many signaling pathways such as mitogenactivated protein kinase (MAPK), protein kinase A (PKA), phosphoinositide 3-kinase (PI3K), protein kinase B (PKB/AKT), nuclear factor κB (NFκB), calcium-and calmodulin-dependent protein kinase II (CaMKII), protein kinase C (PKC), and Ras are involved in the hypertrophic process [5] [6] [7] [8] . Although cardiomyocyte death is believed to be a key feature in the transition from compensated hypertrophy to de-compensated hypertrophy [9, 10] , little is known about the accurate molecular mechanisms that characterize the development of cardiac hypertrophy and the transition to heart failure. Isoproterenol (ISO) is a β-adrenergic receptor agonist that has been used to induce cardiac hypertrophy in vivo and in vitro [4, 11, 12] . ISO also plays a pro-apoptotic role in H9c2 cells [13] .
Oxidative stress occurs when excess reactive oxygen species (ROS) are generated and exceed the ability of intrinsic antioxidant systems [14] . ROS include a number of chemical molecules such as superoxide (O 2− ), hydrogen peroxide (H 2 O 2 ), and hydroxyl radical (·OH) [15] . Accumulating evidence indicates that oxidative stress plays an important role in various heart diseases [16, 17] . Excessive ROS production has been associated with pathological cardiac hypertrophy and heart failure [18] . ROS activate a wide variety of hypertrophy signaling kinases and transcription factors, and mediate apoptosis. Nitric oxide (NO) is an important reactive molecule controlling cardiovascular homeostasis and is necessary for normal cardiac function [15] . Although NO has been described as a member of the free radical family, it is also a free radical scavenger of NO and can react with other ROS to generate less reactive molecules [14] . NO elevates cellular cGMP levels, and in turn, modulates myocyte function, growth, and remodeling [19] . It has been demonstrated that ROS/NO balance plays an important role in the thyroid hormone-induced cardiac hypertrophy [20] .
Thioredoxin (Trx) and peroxiredoxin (Prdx) are cysteinedependent antioxidant proteins in mammalian cells. Trx was first discovered in 1964 as a hydrogen donor for the ribonucleotide reductase [21] . Trx1 is found in the cytosol and nucleus, and can interact with various proteins in a redox-dependent manner, and regulates several intracellular signaling pathways by binding to the apoptosis signal-regulating kinase 1 (ASK-1) and preventing cardiomyocyte apoptosis [22, 23] . Either protein expression or activity of Trx1 was found to be modified in some cardiovascular diseases [17] . Prdx belongs to a diverse family of antioxidant proteins that exhibit peroxidase and chaperone activities and participate in redox signaling [24] . Prdx2 functions as a scavenger of ROS. However, little is known about the role of Prdx2 in cardiac hypertrophy.
In the present study, we used an ISO-induced cardiac hypertrophy model to investigate the mechanism of ISO-induced H9c2 cardiac hypertrophy. The results demonstrate that the balance of NO/ROS in H9c2 cells varies during the development of cardiac hypertrophy. In addition, our data also show that the expression of Trx1 and Prdx2 is decreased during the ISO-induced cardiac hypertrophy, suggesting a critical role of Trx1 and Prdx2 in cardiac hypertrophy.
Materials and Methods

Materials
The JC-1, phalloidin and 2′,7′-dichlorofluorescin diacetate (DCFH-DA) were purchased from Life Technology (New York, USA). Isoprenaline hydrochloride, 4-amino-5-methylamino-2′,7′-difluorofluorescein diacetate (DAF-FM diacetate), Vitamin E (VE), and 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) were from Sigma-Aldrich (St Louis, USA). 4′,6-Diamidino-2-phenylindole (DAPI), and antibodies against Trx1, Prdx2 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were purchased from Abcam (Cambridge, USA). Horseradish peroxidase-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, USA).
Cell culture and treatment
H9c2 cells were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and cultured according to the manuals. H9c2 cells are derived from embryonic rat heart tissue, and exhibit many properties of skeletal muscle. These cells have long been used as a cardiac cell model in a vast number of cardiac hypertrophy studies [11, [25] [26] [27] [28] [29] . The in vitro cardiac hypertrophy experimental model was induced as previously reported [26, 27] 
Cell viability assay
H9c2 cells were seeded at a density of 5 × 10 3 cells/well in 96-well plates. Cell viability in the different treatment groups was assessed by MTT assay. The MTT stock solution (5 mg/ml) was diluted with DMEM to a final concentration of 0.5 mg/ml, and 100 μl was added to each well. After incubation for 4 h at 37°C, the supernatants were discarded and 150 μl DMSO was added to each well to dissolve the formazan crystals. The absorbance of each well was measured at 570 nm using a microplate reader (Perkinelmer, Waltham, USA). 
Assessment of ROS
Determination of nitric oxide
The cellular NO level in H9c2 cells was measured using DAF-FM diacetate. DAF-FM diacetate is cell-permeable and can passively diffuse across the cellular membranes and has been used for the quantitation of low concentration of nitric oxide [28] . H9c2 cells were seeded at a density of 2 × 10 4 cells/well in 24-well plates. At the end of ISO treatment, H9c2 cells in different groups were exposed to 10 μM DAF-FM diacetate in Tyrode's solution for 30 min at 37°C and washed with PBS for three times to remove excessive probe. The cells were then incubated in Tyrode's solution for 10 min to allow complete de-esterification of the intracellular diacetates. The NO fluorescence intensity was analyzed by the confocal microscope at 488 nm excitation and 515 nm emission.
MMP measurement
Mitochondrial membrane potential (MMP) was elevated by JC-1 staining. Briefly, H9c2 cells were seeded at a density of 2 × 
Real-time PCR
Total RNA was isolated from H9c2 cells using the TRIzol reagent (Invitrogen, Carlsbad, USA). Double-stranded cDNA was prepared from 2 μg of total RNA using the Superscript TM Choice kit (Invitrogen). Real-time PCR was performed using the primers listed in Table 1 . After denaturation at 94°C for 30 s, amplification was performed in 40-45 cycles at 94°C for 10 s, 58°C for 10 s, and 72°C for 15 s. Fluorescence data were acquired after the extension step in the PCR reaction. Quantitative real-time PCR analysis was repeated at least three times.
Western blot analysis
Cells were lysed with RIPA buffer (DINGGUO, Beijing, China) containing 1 μM PMSF (Sigma-Aldrich). Proteins were resolved by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, USA). The membranes were blocked with Trisbuffered saline containing 0.2% Tween 20 and 5% fat-free dried milk. The membranes were then incubated sequentially with primary antibodies and then horseradish peroxidase-conjugated secondary antibodies. Specific proteins were detected with the enhanced chemiluminescence detection reagent (Pierce, New York, USA) according to the manufacturer's protocol.
Immunofluorescence microscopy and measurement of cell surface area
Cells cultured in six-well plates were fixed with 4% paraformaldehyde for 30 min, permeated with PBS containing 0.5% Triton X-100 for 20 min and then blocked with 2% bovine serine albumin in PBS for 30 min at room temperature. The cells were then incubated in succession with phalloidin for 40 min, followed by staining with DAPI for 5 min. Cells were analyzed and images were captured using the confocal microscope. Then ZEN2011 processing software was used to calculate the single cell surface area. Four random photographs were taken from each well, and 5-10 single cells which can be distinguished from other cells on each graphic were selected to measure the cell surface area. Measurements were performed in triplicate.
Statistical analysis
Data are expressed as the mean ± SEM, and experiments were repeated three times. Statistical analyses were performed using the Student's t-test. P values <0.05 were considered of significant difference.
Results
ISO treatment induces cardiac hypertrophy
ISO is a nonselective β-adrenergic receptor agonist which has been used for the study of cardiac hypertrophy. In this study, H9c2 cells were treated with 10 μM ISO for 48 h. The results showed that ISO treatment led to significant cardiomyocyte hypertrophy in H9c2 cells as indicated by the increased cell surface area (Fig. 1A,B) and upregulation of the expressions of fetal genes ANP and β-MHC (Fig. 1C,D) . The above evidence exhibited that the H9c2 cardiac hypertrophy model was successfully established.
Effect of ISO on cell surface area, cell viability, and MMP
After pathological stimulation, the heart undergoes a compensatory response with normal function and increased size, which then will result in de-compensated heart failure. In order to investigate the mechanism of cardiac hypertrophy development due to chronic ISO treatment, we measured the cell surface area and cell viability of H9c2 cells after ISO treatment for 24, 48, and 72 h. As shown in Fig. 2 , cell surface area exhibited a significant increase in a time-dependent manner. ISO treatment also resulted in a significant time-dependent down-regulation in MMP in H9c2 cells (Fig. 3A,B) . Interestingly, the cell viability was not significantly decreased after ISO treatment for 24 and 48 h, but showed a significant decrease after ISO treatment for 72 h, when compared with the control (Fig. 3C) .
ISO treatment induces ROS production and results in a NO/ROS imbalance
Excessive ROS production has been associated with pathological cardiac hypertrophy and heart failure, while NO is an important reactive molecule controlling cardiovascular homeostasis and is necessary for normal cardiac function [14, 17] . Our results showed that ROS concentration was increased in H9c2 cells treated with ISO (Fig. 4A,B) . In order to determine whether ISO-induced ROS overload contributes to cardiac hypertrophy, H9c2 cells were treated with ISO and VE, a type of antioxidant that can eliminate cellular ROS [20] . The results showed that VE significantly decreased cellular ROS, but had no effect on cell surface area ( Supplementary Fig. S1 ), suggesting that ISO-induced cardiac hypertrophy is not caused by ROS overload. It was also found that ISO treatment significantly resulted in an up-regulation of NO concentration as a negative feedback regulator of ISO-induced cardiac hypertrophy, and the NO concentration was largely up-regulated after 24 h of ISO treatment (Fig. 4C,D) . There results demonstrated that, ISO induced an imbalance in NO/ROS, which was gradually decreased with increasing treatment time (Fig. 4E) .
The expressions of Trx1 and Prdx2 vary during the ISO-induced cardiac hypertrophy
Both Trx1 and Prdx2 are cysteine-dependent antioxidant proteins in mammalian cells. ISO-induced cardiac hypertrophy is consistent with elevated cellular ROS, but the mechanism of ROS overload is not clear. To gain mechanistic insight into the development of cardiac hypertrophy, real-time PCR and western blot analysis were performed to examine the expression of Trx1 and Prdx2 in H9c2 cells with normal viability and reduced viability. As shown in Fig. 5 , the expressions of Trx1 and Prdx2 were both significantly down-regulated after ISO treatment for 72 h. Interestingly, Prdx2 showed an elevated expression during the first 24 h of ISO treatment and then decreased with extended treatment time. These findings suggest a critical role for Trx1 and Prdx2 in the cardiac hypertrophy and in the transition from compensatory hypertrophy to de-compensatory hypertrophy.
Discussion
Cardiovascular diseases are the leading causes of death and disability worldwide. The development of pathological cardiac hypertrophy plays a critical role in these diseases [30] . Cardiac hypertrophy is a compensatory response to the chronic stress or disease, which can result in de-compensated hypertrophy and can ultimately lead to heart failure. In the present study, for the first time, we demonstrated the changes of NO/ROS balance during ISO-induced cardiac hypertrophy development. And this phenomenon was consistent with the changes of Trx1 and Prdx2 expression which were revealed for the first time in ISO-induced cardiac hypertrophy.
Understanding the molecular mechanism responsible for the induction of cardiac hypertrophy has been of great interest due to the known association between cardiac hypertrophy and nearly all forms of heart failure [31] . Our studies showed that, ISO treatment for 48 h induced an increase in cell surface area and fetal gene ANP and β-MHC expression, and indicated that the cardiac hypertrophy model was successfully established. Results showed that ISO treatment for 24 and 48 h induced H9c2 cell hypertrophy with normal cell viability, but cell surface area was increased and cell viability was significantly decreased (Fig. 3C) . MMP is important for adenosine triphosphate (ATP) generation and for maintaining the complete function of mitochondrial [32] . Our results showed that cell MMP was down-regulated by ISO treatment (Fig. 3A,B) . This indicates that H9c2 cells are compensatory when treated with ISO for 24 and 48 h, but then develop into decompensated hypertrophy after 72 h of treatment with ISO. Oxidative stress, defined as an excessive production of ROS, is enhanced in heart failure [33] . ROS participate in pathologic biochemical reactions and include free radicals such as superoxide and hydroxyl radical [34] . It has been demonstrated that ROS play a paradoxical role in cardiomyocytes. Low amounts of ROS produced in ischemic preconditioning (IPC) and hypoxic preconditioning (HPC) are beneficial, while high levels of ROS contribute to cardiomyocyte damage and ischemic injury [35] . It was reported that antioxidants completely abolish cardioprotection due to IPC [36] . It was also reported that a burst of O 2− at early ischemia may be correlated with IPC [37] . However, excessive ROS production can cause cellular dysfunction, protein and lipid peroxidation, and DNA damage, which eventually results in irreversible cell damage and death [15, 37] . Many studies have proved that ROS are implicated in the pathogenesis of cardiac hypertrophy and heart failure [38] . ROS are formed by several mechanisms including activation of nicotinamideadenine dinucleotide phosphate (NADPH) oxidase, uncoupling of NO synthase (NOS), xanthine oxidase (XO), and electron transport and 'leakage' during phosphorylation [15] . Our study demonstrated that ROS production was increased after ISO treatment for 24, 48, and 72 h. Interestingly, there was no significantly difference between 24 and 48 h, but significantly up-regulation was seen at 72 h compared with 24 and 48 h (Fig. 4A,B) . These findings were consistent with the cell viability results which showed a different tendency at 24, 48, and 72 h. NO, which is generated by NO synthase, is necessary for normal cardiac physiology and protects against apoptosis through the NOcGMP pathway [19, 39] . There are two pathways for NO signal regulation, cGMP-dependent and cGMP-independent pathway, both play a protective role [40] . Our results showed that cellular NO levels were elevated following ISO treatment for 24 and 48 h, which plays a protective role in ISO-induced cell function downregulation as a compensatory reaction. This may explain the normal cell viability after 24 and 48 h of ISO treatment. However, after ROS burst at 72 h, the NO level is unable to inhibit excessive ROSinduced cell injury, resulting in a decrease in cell viability at 72 h (Fig. 4) . As an antioxidant, NO can also inhibit the activity of XO and NADPH oxidase [15, [41] [42] [43] [44] , and then reduce the production of ROS. Combined with cellular NO and ROS signals, the NO/ROS balance was damaged after ISO treatment and was significantly down-regulated at 72 h. It is noteworthy that the trend of NO/ROS decrease was similar to the results of MMP. These findings indicate that the NO/ROS balance is important in the transition from compensated hypertrophy to de-compensated hypertrophy, and this imbalance is mainly determined by excessive ROS production.
Both Trx and Prdx are antioxidant and redox-signaling proteins and are abundant in the heart [21, 45] . Prdx2 can prevent monocyte attachment to endothelial cells in response to treatment with oxidized low density lipoprotein (LDL) [46] . In addition, expression of Prdx2 decreases in hearts of ischemia reperfusion (I/R) and is up-regulated in idiopathic dilated cardiaomyopathy patients [47, 48] . Trx1 overexpression inhibits cardiac hypertrophy and reduces oxidative stress in response to pressure overload, while Trx1 deficiency elevates oxidative stress and then induces cardiac hypertrophy [17] . The translocation from nucleus to cytoplasm of class II histone deacetylases (HDACs) is considered as the common final pathway of cardiac hypertrophy [48, 49] . Trx1 can inhibit cardiac hypertrophy by reducing class II HDAC4 oxidized by hypertrophic stimuli and then restore the nuclear localization of HDAC4 [50, 51] . However, the expression of Trx1 and Prdx2 in the development of cardiac hypertrophy and the transition from compensated hypertrophy to de-compensated hypertrophy has not been investigated. Our results show that the expressions of Trx1 and Prdx2 are down-regulated after ISO treatment, which is consistent with the significant up-regulation of cellular ROS production. Prdx2 expression shows a little but significant increase after ISO treatment for 24 h, but is down-regulated after 48 h, and eventually exhibits a significant decrease at 72 h. Trx1 inhibits the production of ROS, which can reverse the hypertrophy stimulation of HDAC4, CaMKII, and ROS [40, 51] . Prdx2 can neutralize the cellular ROS [52] . The down-regulation of Trx1 and Prdx2 may play an important role in ISO-induced cardiac hypertrophy. With increased duration of ISO treatment, the NO/ROS balance shows a significant down-regulation, Prdx2 expression exhibits a down-regulation, and the cell viability and MMP show a significant down-regulation. According to these results, we suggest that the elevated Prdx2 acts as a negative feedback regulator of ISO-induced cardiac hypertrophy.
The above results demonstrate that ISO-induced cardiac hypertrophy involves decreased MMP, cellular ROS burst, decreased cell viability and decreased Trx1 and Prdx2 expression. It is known that cellular ROS overload can induce cardiac hypertrophy [52] . Therefore, we used the antioxidant VE to eliminate cellular ROS induced by ISO, and then assessed cell surface area. The results showed that VE significantly inhibited cellular ROS, but did not affect cell surface area. This indicated that ROS overload is induced by ISO-induced cardiac hypertrophy, but cardiac hypertrophy is not caused only by ROS overload in our cardiac hypertrophy model.
In summary, the results of this study show that NO/ROS balance plays an important role in the development of ISO-induced cardiac hypertrophy. In addition, the down-regulation of Trx1 and Prdx2 is involved in the cardiac hypertrophy and the transition from compensatory hypertrophy to de-compensatory hypertrophy. Trx1 and Prdx2 may be potential therapeutic targets for the treatment of cardiac hypertrophy. The mechanism of Prdx2 in protecting cell viability requires further study.
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